Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Domingo-Domènech E, Pro B, Illidge T, Horwitz S, Trumper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Kim WS, Feldman T, Choi I, Gritti G, Belada D, Shustov A, Illes A, Zinzani PL, Hüttmann A, Trneny M, Le Gouill S, Jagadeesh D, Friedberg JW, Little M, Dong C, Fanale M, Fenton K, Savage KJ

Open source

DOI: 10.1038/s41408-025-01329-2
Published: 2025 Aug 1
Container: Blood cancer journal
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-025-01329-2,
  title = {Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.},
  author = {Domingo-Domènech E and Pro B and Illidge T and Horwitz S and Trumper L and Iyer S and Advani R and Bartlett NL and Christensen JH and Kim WS and Feldman T and Choi I and Gritti G and Belada D and Shustov A and Illes A and Zinzani PL and Hüttmann A and Trneny M and Le Gouill S and Jagadeesh D and Friedberg JW and Little M and Dong C and Fanale M and Fenton K and Savage KJ},
  year = {2025},
  journal = {Blood cancer journal},
  doi = {10.1038/s41408-025-01329-2},
  url = {https://doi.org/10.1038/s41408-025-01329-2}
}

RIS

TY  - JOUR
TI  - Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.
AU  - Domingo-Domènech E
AU  - Pro B
AU  - Illidge T
AU  - Horwitz S
AU  - Trumper L
AU  - Iyer S
AU  - Advani R
AU  - Bartlett NL
AU  - Christensen JH
AU  - Kim WS
AU  - Feldman T
AU  - Choi I
AU  - Gritti G
AU  - Belada D
AU  - Shustov A
AU  - Illes A
AU  - Zinzani PL
AU  - Hüttmann A
AU  - Trneny M
AU  - Le Gouill S
AU  - Jagadeesh D
AU  - Friedberg JW
AU  - Little M
AU  - Dong C
AU  - Fanale M
AU  - Fenton K
AU  - Savage KJ
PY  - 2025
JO  - Blood cancer journal
DO  - 10.1038/s41408-025-01329-2
UR  - https://doi.org/10.1038/s41408-025-01329-2
ER  -

APA

E, D., B, P., T, I., S, H., L, T., S, I., R, A., NL, B., JH, C., WS, K., T, F., I, C., G, G., D, B., A, S., A, I., PL, Z., A, H., M, T., S, L. G., D, J., JW, F., M, L., C, D., M, F., K, F., & KJ, S. (2025). Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.. Blood cancer journal. https://doi.org/10.1038/s41408-025-01329-2

Source records

pubmed · retrieved 2026-09-26T22:43:45.233Z